NCT06271512View on ClinicalTrials.gov

A Study of Participants with Β-Thalassemia Treated with Betibeglogene Autotemcel

RecruitingOBSERVATIONAL
Enrollment

150

Participants

Timeline

Start Date

January 23, 2024

Primary Completion Date

December 31, 2043

Study Completion Date

December 31, 2043

Conditions
Beta-Thalassemia
Interventions
OTHER

No Intervention

This is non-interventional study.

Trial Locations (6)

11040

RECRUITING

Cohen Children's Medical Center, New Hyde Park

19104

RECRUITING

Children's Hospital of Philadelphia, Philadelphia

55455

RECRUITING

University of Minnesota, Minneapolis

77030

RECRUITING

Texas Children's Hospital, Houston

94043

RECRUITING

Stanford University, Palo Alto

94609

RECRUITING

UCSF Benioff Children's Hospitals, Oakland

Sponsors
All Listed Sponsors
collaborator

Center for International Blood and Marrow Transplant Research

NETWORK

lead

Genetix Biotherapeutics Inc.

INDUSTRY

NCT06271512 - A Study of Participants with Β-Thalassemia Treated with Betibeglogene Autotemcel | Biotech Hunter | Biotech Hunter